All Articles
On June 18, 2025, the FDA approved tafasitamab-cxix (Monjuvi; Incyte) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. Read More ›
Dr. Walter Stadler shares insights on the current treatment landscape for prostate and bladder cancers and emphasizes the importance of improving access to care for all patients. Read More ›
Dr. Enrique Velazquez Villarreal, Assistant Professor in Department of Integrative Translational Sciences at City of Hope, discusses how his innovative AI tool, AI-HOPE, is revolutionizing cancer care by combining clinical data, genomics, and social determinants of health to enhance personalized treatments and patient outcomes. Read More ›
Advances in technology, including artificial intelligence and telemedicine platforms, offer promising avenues to support precision oncology efforts remotely. Read More ›
The Department of Veterans Affairs has been able to “dramatically increase” clinical trial opportunities and participation over the past 2 years, thanks in part to a joint initiative from the Prostate Cancer Foundation and Veterans Affairs,... Read More ›
Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer may vary depending on demographic and sociological patterns,... Read More ›
The phase 3 DeLLphi-304 study evaluated tarlatamab, a bispecific T-cell engager immunotherapy, versus chemotherapy in patients with small cell lung cancer that progressed on or after platinum-based chemotherapy. Read More ›
The phase 3 IMforte study evaluated the efficacy and safety of first-line maintenance treatment with lurbinectedin combined with atezolizumab versus atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›
Nurses and navigators, especially those embedded in community programs, can help bridge the access gap by promoting education, building trust, and facilitating access early in the patient journey. Read More ›
The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center. Read More ›